Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (175)	2/22/1999 11:21:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

It is a great deal. The powers that be, again, just decided to take down biotechs that have a decent research premium. You can thank those with the "buy biotech in the Fall and sell after H&Q mentality". They have no way to gauge science because they don't understand it. And, if they pay someone that does understand it to study a company, it will be doubly obvious that they don't. Thus, we have the management of Franklin funds, etc. Yeah, that's the second supplement on Bioentrepreneurship. I liked the article from Novartis...... sort of costly to do that (establish a genomics infrastructure) from the pharma perspective, huh? :-)